IS2321B - Aðferðir og blöndur til að fyrirbyggja þol gegn berkjuvíkkandi lyfjum - Google Patents

Aðferðir og blöndur til að fyrirbyggja þol gegn berkjuvíkkandi lyfjum

Info

Publication number
IS2321B
IS2321B IS5928A IS5928A IS2321B IS 2321 B IS2321 B IS 2321B IS 5928 A IS5928 A IS 5928A IS 5928 A IS5928 A IS 5928A IS 2321 B IS2321 B IS 2321B
Authority
IS
Iceland
Prior art keywords
bronchodilator
preparations
tolerance
prevention
methods
Prior art date
Application number
IS5928A
Other languages
English (en)
Other versions
IS5928A (is
Inventor
Tahir Ahmed
Original Assignee
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26803748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2321(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ivax Research Inc filed Critical Ivax Research Inc
Publication of IS5928A publication Critical patent/IS5928A/is
Publication of IS2321B publication Critical patent/IS2321B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IS5928A 1998-10-30 2001-04-27 Aðferðir og blöndur til að fyrirbyggja þol gegn berkjuvíkkandi lyfjum IS2321B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10650798P 1998-10-30 1998-10-30
US09/362,540 US6235725B1 (en) 1998-10-30 1999-07-28 Methods and compositions for the prevention of tolerance to medications
PCT/US1999/024034 WO2000025723A2 (en) 1998-10-30 1999-10-13 Methods and compositions for the prevention of tolerance to medications

Publications (2)

Publication Number Publication Date
IS5928A IS5928A (is) 2001-04-27
IS2321B true IS2321B (is) 2007-12-15

Family

ID=26803748

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5928A IS2321B (is) 1998-10-30 2001-04-27 Aðferðir og blöndur til að fyrirbyggja þol gegn berkjuvíkkandi lyfjum

Country Status (25)

Country Link
US (1) US6235725B1 (is)
EP (1) EP1124563B1 (is)
JP (1) JP4585121B2 (is)
CN (2) CN1329496A (is)
AR (2) AR023911A1 (is)
AT (1) ATE277621T1 (is)
AU (1) AU760119B2 (is)
BR (1) BR9915818A (is)
CA (1) CA2348926C (is)
CO (1) CO5160320A1 (is)
CY (1) CY1107493T1 (is)
CZ (1) CZ297914B6 (is)
DE (1) DE69920734T2 (is)
ES (1) ES2228173T3 (is)
HK (1) HK1041596A1 (is)
HU (1) HUP0302492A3 (is)
IL (2) IL142865A0 (is)
IS (1) IS2321B (is)
NO (1) NO333194B1 (is)
NZ (1) NZ511399A (is)
PL (1) PL195592B1 (is)
PT (1) PT1124563E (is)
SK (1) SK285150B6 (is)
TW (1) TW565451B (is)
WO (1) WO2000025723A2 (is)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
DE50103551C5 (de) * 2000-10-12 2014-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue tiotropium-haltige inhalationspulver
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
CA2516331C (en) * 2002-02-18 2013-04-23 University Of Southampton Combination therapy using glycosaminoglycans and therapeutic agents for the treatment of respiratory disorders
EP1511466B2 (en) * 2002-02-18 2015-02-25 Ockham Biotech Limited Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
ES2527096T3 (es) * 2002-02-18 2015-01-20 Ockham Biotech Limited Combinación de ADNasa I y glucosaminoglucanos para su uso en limpieza de ADN extracelular
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
JP2006501815A (ja) * 2002-04-25 2006-01-19 モメンタ ファーマシューティカルズ インコーポレイテッド 粘膜送達のための方法および製品
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US7763280B2 (en) * 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
EP1625851A4 (en) 2003-05-16 2007-12-26 Bbk Bio Corp PREPARATION FOR PREVENTING CONTACT OF PATHOGEN BROOMS WITH A LIVING ORGANISM
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050043343A1 (en) * 2003-07-28 2005-02-24 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
MX2007001903A (es) 2004-08-20 2007-08-02 Mannkind Corp Catalisis de sintesis de dicetopiperazina.
KR101306384B1 (ko) 2004-08-23 2013-09-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
JP5465878B2 (ja) 2005-09-14 2014-04-09 マンカインド コーポレイション 活性薬剤に対する結晶性微粒子表面の親和性を増大させることに基づく薬物処方の方法
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN104689432B (zh) 2008-06-13 2018-07-06 曼金德公司 干粉吸入器和用于药物输送的系统
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
EP2440184B1 (en) 2009-06-12 2023-04-05 MannKind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US20130090371A1 (en) * 2010-04-20 2013-04-11 President And Fellows Of Harvard College Methods and compositions for inhibition of beta2-adrenergic receptor degradation
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
DK2694402T3 (en) 2011-04-01 2017-07-03 Mannkind Corp BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CN104069497A (zh) * 2014-06-27 2014-10-01 东莞市凯法生物医药有限公司 一种降低药物耐受性的组合物、方法及其应用
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20190070244A1 (en) * 2017-06-30 2019-03-07 The New Zealand Institute For Plant And Food Research Limited Boysenberry compositions and methods of preparation and use thereof
EP3664826A4 (en) 2017-08-08 2021-04-28 Odette M. Shaw BOYSBERRY, APPLE AND CURRANT COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
US5192548A (en) 1990-04-30 1993-03-09 Riker Laboratoires, Inc. Device
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
JP3280974B2 (ja) 1991-12-12 2002-05-13 グラクソ、グループ、リミテッド 医 薬
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
AU673660C (en) * 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Also Published As

Publication number Publication date
SK5902001A3 (en) 2002-07-02
CN100352448C (zh) 2007-12-05
EP1124563A2 (en) 2001-08-22
IL142865A0 (en) 2002-03-10
ES2228173T3 (es) 2005-04-01
DE69920734D1 (de) 2004-11-04
WO2000025723A2 (en) 2000-05-11
HK1041596A1 (zh) 2002-07-12
AR023911A1 (es) 2002-09-04
EP1124563B1 (en) 2004-09-29
IS5928A (is) 2001-04-27
WO2000025723A3 (en) 2000-07-27
BR9915818A (pt) 2002-06-18
CZ20011518A3 (cs) 2002-04-17
HUP0302492A2 (hu) 2003-11-28
AR082913A2 (es) 2013-01-16
CO5160320A1 (es) 2002-05-30
JP2002535245A (ja) 2002-10-22
PL364727A1 (en) 2004-12-13
AU760119B2 (en) 2003-05-08
CZ297914B6 (cs) 2007-04-25
EP1124563A4 (en) 2002-01-02
CN1572303A (zh) 2005-02-02
JP4585121B2 (ja) 2010-11-24
NO20012097L (no) 2001-06-15
DE69920734T2 (de) 2005-10-06
NO20012097D0 (no) 2001-04-27
SK285150B6 (sk) 2006-07-07
HUP0302492A3 (en) 2005-05-30
PL195592B1 (pl) 2007-10-31
CA2348926A1 (en) 2000-05-11
AU1205100A (en) 2000-05-22
ATE277621T1 (de) 2004-10-15
CN1329496A (zh) 2002-01-02
CY1107493T1 (el) 2013-03-13
NO333194B1 (no) 2013-04-02
CA2348926C (en) 2011-08-23
TW565451B (en) 2003-12-11
PT1124563E (pt) 2005-01-31
IL142865A (en) 2006-07-05
NZ511399A (en) 2004-09-24
US6235725B1 (en) 2001-05-22

Similar Documents

Publication Publication Date Title
IS2321B (is) Aðferðir og blöndur til að fyrirbyggja þol gegn berkjuvíkkandi lyfjum
DK1112174T3 (da) Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf
DK0789568T3 (da) Antineoplastiske kakaoekstrakter, fremgangsmåder til fremstilling og anvendelse
DK0811006T3 (da) Benzopyranholdige forbindelser og fremgangsmåde til deres anvendelse
NO991676L (no) FremgangsmÕter og sammensetninger for immunmodulering
NO990296D0 (no) HPPD-genet og inhibitorer
NO985278L (no) Elektromagnetiske-til-akustiske og akustiske-til-elektro-magnetiske forsterkere og fremgangsmÕter for bruk av disse
IS5943A (is) Aðferð og samsetningar til að endurheimta samræmdan stöðugleika próteina af p53 ættinni
NO931873D0 (no) Fremgangsmaate og system for geometrimaaling
NO20016277L (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske sammensetninger
NO993514D0 (no) Gjennomformasjons elektromagnetisk telemetrisystem og fremgangsmåte for anvendelse av samme
DK1126876T3 (da) Adjuvanssystemer og vacciner
NO20002846L (no) Inhaleringsanordning og fremgangsmÕte ved samme
NO20012940L (no) Fremgangsmåter og sammensetninger for å redusere permeabilitetene til underjordiske soner
DK1032408T3 (da) Galenisk præparat til forebyggelse og behandling af leverkarcinom
NO995090L (no) Kilesystem og utløsningsmetoder
DK0991666T3 (da) Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf
DK1109625T3 (da) Pulverisator og fremgangsmåde til pulverisering
NO995324L (no) Baerer for gjenstander og emne for denne
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
AU2001245288A1 (en) Overhanging form system and method of using the same
DK1003383T3 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
NO20010119D0 (no) Preparater omfattende GABA-analoger og kaffein
NO20006059L (no) Sammensatt element og fremgangsmåte for anvendelse
NO993030D0 (no) FremgangsmÕte og system for Õ skaffe forbindelser